Eastern Bank’s Charles River Laboratories CRL Stock Holding History

Eastern Bank’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-34	Closed	-$5.32K	–	1182
2025 Q3	$5.32K	Buy	+34	New	+$5.4K	﹤0.01%	902

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Eastern Bank's CRL Position: Q4 2025 in Review

Eastern Bank sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 34 shares — an estimated $5.32K sold.

Eastern Bank first reported a position in CRL in Q3 2025 and held it in 1 quarter. The position peaked at $5.32K in Q3 2025. 583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

Eastern Bank reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
Eastern Bank sold 34 Charles River Laboratories shares in Q4 2025, an estimated $5.32K.
Eastern Bank first reported a position in Charles River Laboratories in Q3 2025 and held it in 1 quarter.
Eastern Bank's Charles River Laboratories position peaked at $5.32K in Q3 2025.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Eastern Bank's 13F filing for Q4 2025, filed 14 Jan 2026.